Bristol-Myers Squibb Immuno-Oncology Pipeline — HyperCore KM Decomposition
Bristol-Myers Squibb
HyperCore 320-classifier KM decomposition of the multi-organ compound signals (PD-1/PD-L1 + CTLA-4) driving the CheckMate-class OS inflection in Bristol-Myers Squibb's immuno-oncology pipeline — responder/non-responder attribution at the KM curve knee for the next-trial label-expansion conversation.
Substrate: publicly disclosed CheckMate-class immuno-oncology OS dataset (Opdivo + Yervoy) · HyperCore 320-classifier stack
The immuno-oncology read frames the inflection as a multi-organ compound signal: PD-1/PD-L1 + CTLA-4 co-attribution across the publicly disclosed Opdivo (nivolumab) + Yervoy (ipilimumab) CheckMate-class OS datasets is the highest-weight classifier decomposition in the HyperCore stack, ahead of any single-mechanism read. The decomposition is the shape a paid Tier 1 deliverable would carry — classifier-weighted, auditable, and keyed to the next-trial label-expansion conversation rather than the closed-out data cut.
Scope the Bristol-Myers Squibb pilot →Audit-trail parity. The comparable KEYNOTE-789 sample — same HyperCore decomposition, same three-artifact ship set, same narrative shape — is readable end-to-end at /keynote-789-report. Use the KEYNOTE-789 read as the prior sample to walk a Bristol-Myers Squibb reviewer through before scoping the pilot engagement.
Every Bristol-Myers Squibb Engagement Ships Three Artifacts
Each Trial Intelligence Report ships in three formats so the sponsor can read however they read. Mirrors the three-ship model used on every prior engagement so a Bristol-Myers Squibb reviewer can audit any prior deliverable in the same shape.
| Artifact | Format | What It Contains |
|---|---|---|
| HTML | 4-page printable | Numbered pages, inline SVG KM chart, 12-row classifier attribution table, decision narrative. Designed for first-pass Tier 1 sponsor review. |
| CSV | Auditable raw data | KM curves (24 monthly rows per arm) plus classifier-attribution table with weights, direction, classifier IDs (I50, N17, E11, A41, D64 — and additional immuno-oncology / CheckMate-class classifiers), and notes. Importable into R, Python, or Excel for re-analysis. |
| Markdown | Version-controlled narrative | Page-by-page decision narrative with editorial hooks, decision-implications section for next-trial label-expansion framing, and a closing paid-pilot CTA. Diff-able across report revisions. |
All three formats ship on the same day. The CSV and markdown are auditable companions to the HTML — reviewers who want to re-derive the chart or check the classifier weights against their own read can do so without leaving the engagement scope.
The CTA routes into the existing Trial Intelligence Report lead form — your request lands in lead_captures, and we respond within one business day with a scoping read on which tier (single-trial brief, comparative brief, or engagement-scope pilot) fits the publicly disclosed dataset.
Scope the Bristol-Myers Squibb pilot →What happens after you click through. You land on /trial-intelligence-report, the existing lead form posts to /api/leads, and the row lands in lead_captures for the audit trail. No NDA required to scope — NDA only if you want Tier 3 with an in-person working session.